Skip to main content

Table 3 Evolution of eGFR and BMI over 24 months of treatment in intention-to-treat and per-protocol population

From: A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease

No. of patients Study period Mean eGFR value (ml/min/1.73m2) Mean eGFR change
(ml/min/1.73m2)
95% CI P Value Mean BMI Value
(kg/m2)
Mean BMI change
(kg/m2)
95% CI P Value
A. Mean eGFR and BMI changes in intention to treat population
 34 Baseline 60.45 ± 34.71 27.10 ± 3.65
 28 1 month 61.41 ± 34.17 0.96 −16.63 to −18.55 0.91 26.94 ± 3.58 −0.16 −2.00 to 1.68 0.86
 25 4 months 62.16 ± 34.53 1.71 −16.56 to 19.98 0.85 26.45 ± 3.48 − 0.65 − 2.53 to 1.23 0.49
 20 12 months 59.42 ± 37.67 −1.03 − 21.28 to 19.22 0.91 26.27 ± 3.32 −0.80 −2.82 to 1.16 0.40
 16 24 months 58.88 ± 32.32 −1.57 −22.28 to 19.14 0.87 26.00 ± 3.07 −1.10 −3.22 to 1.02 0.30
B. Mean eGFR and BMI changes in per protocol population
 16 Baseline 63.45 ± 32.68 26.80 ± 3.76
 16 1 month 64.83 ± 31.68 1.38 −21.85 to 24.61 0.90 26.56 ± 3.82 −0.24 −2.97 to 2.49 0.85
 16 4 months 65.26 ± 30.65 1.81 −21.60 to 24.68 0.87 26.34 ± 3.60 −0.46 −3.11 to 2.19 0.76
 16 12 months 62.80 ± 34.58 −0.65 −24.94 to 23.64 0.95 26.31 ± 3.46 −0.49 − 3.09 to 2.11 0.70
 16 24 months 58.88 ± 32.32 − 4.57 −28.03 to 18.89 0.69 26.00 ± 3.07 −0.80 −3.27 to 1.67 0.51
  1. No. number, CI confidence interval, eGFR estimated glomerular filtration rate, BMI body mass index
\